H. Daniel Lacorazza, PhD
- Pathology
Principal Investigator, Department of Pathology
Professor, Department of Pathology & Immunology, Baylor College of Medicine
Phone:
832-824-5103
Languages: English, Spanish
Departments:
Get to know H. Daniel Lacorazza, PhD
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center | Fellowship | 1999 | |
| National Institutes of Health | Fellowship | 1995 | |
| University of Buenos Aires | PhD | Doctor of Philosophy | 1992 |
Organizations
| Organization Name | Role |
|---|---|
| American Society of Hematology | Member |
| Society for Leukocyte Biology | Member |
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Dr. Lacorazza’s lab investigates the genetic regulation of both normal and malignant hematopoiesis. It examines the genes that govern the self-renewal of hematopoietic and leukemia stem cells by using a combination of genetic mouse models and patient-derived xenograft models to identify molecular targets for developing alternative therapies for pediatric leukemia. Dr. Lacorazza’s lab collaborates with the Center for Drug Discovery at Baylor College of Medicine and a medicinal chemistry team at Northwestern University to discover and design novel kinase inhibitors tested in preclinical mouse leukemia models.
Bridges, CS; Chen, TJ; Puppi, M; Rabin, KR; Lacorazza, HD. Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia. Blood Advances, 2023; 7(3):422-435
Lacorazza, HD. Pharmacological inhibition of the MAP2K7 kinase in human disease. Frontiers in Oncology, 2024; 14:1486756
Kim, DR; Orr, MJ; Kwong, AJ; Deibler, KK; Munshi, HH; Bridges, CS; Chen, TJ; Zhang, X; Lacorazza, HD; Schedit, KA. Rational design of highly potent and selective covalent MAP2K7 inhibitors. ACS Medicinal Chemistry Letters, 2023; 14:606-613